Mette Husbyn

Mette Husbyn currently serves as the Chief Technology Officer at Lytix Biopharma since February 2025, previously holding the CTO position at Nykode Therapeutics from October 2017 to January 2025. Husbyn has extensive experience at Lytix Biopharma, where responsibilities included leading Chemistry, Manufacturing, and Controls (CMC) activities for both infection and cancer projects from April 2012 to October 2017. Prior roles include Department Manager for Analytical Development and Documentation at GE Healthcare, where oversight of a team of scientists was a key responsibility, and earlier work as a Research Scientist at Nycomed Bioreg and as an Analytical Scientist at Nordisk Analyse Center. Academic credentials include a PhD in Peptide Synthesis, Anti-thrombotics, and In Vitro Assays from the University of Oslo, alongside a degree in Organic Chemistry from the Norwegian University of Science and Technology (NTNU).